Isomorphic Labs
AI-first drug discovery heading to the clinic
At a glance
- Category
- AI Biotech & Drug Discovery
- Product type
- AI drug-discovery company
- Status
- Private (research company)
- Launch
- November 17, 2026 ($5B Series C)
- Pricing
- Not applicable — research company, not a self-serve product.
Overview
Isomorphic Labs (spun out of Google DeepMind) closed an oversubscribed $5 billion Series C on November 17, 2026 to advance its AI drug-design engine and take candidates toward clinical trials.
Why it matters
A $5B Series C (Nov 17) to move AI-designed drugs toward clinical trials is the edition's defining biotech-AI event — though funding is a signal, not proof of clinical success.
Problem it solves
How it works
Key capabilities
- AI drug-design engine
- Protein-structure-informed methods
- Pharma partnerships
- $5B Series C (Nov 17)
Integrations
Pricing & plans
Not applicable — research company, not a self-serve product.
View official pricing ↗Use cases
- Early-stage drug discovery
- Target & molecule design
- Pipeline development
Who should use it
- • Pharma partners and researchers
- • Investors tracking AI-bio
May not suit
- • Developers seeking a usable API or product today
Independent editorial analysis
Strengths & limitations
Strengths
- +Builds on DeepMind's protein-structure breakthroughs
- +Exceptional capital runway after $5B raise
- +Pharma partnerships and an internal pipeline
Limitations
- –Not a self-serve product — no public access
- –Funding does not guarantee clinical or regulatory success
Editorial assessment by aitoolslist.ai, distinct from vendor claims.
Alternatives & comparison
| Option | Positioning | When to prefer |
|---|---|---|
| Isomorphic Labs | AI-first drug discovery heading to the clinic | Featured pick this edition |
| Recursion | AI-driven drug discovery (public) | For a public company with a clinical pipeline. |
| Insilico Medicine | Generative chemistry | For end-to-end generative drug design. |
| Iambic | AI drug discovery | For physics-informed ML drug design. |
Comparison reflects positioning; pricing and spec parity are not independently verified across all options.
Edition intelligence · AI Biotech & Drug Discovery
Why it was selected this edition
The edition's defining biotech-AI story (Nov 17). Note: funding is a supporting signal, not proof of product/clinical success — flagged for editorial verification.
Claim-level transparency
Research & verification
Our verification scope is explicit. A checked website does not mean the whole product has been independently audited.
| Official website | Confirmed | https://www.isomorphiclabs.com |
| Launch / announcement | Confirmed | |
| Product capabilities | Cross-checked | From cited sources |
| Pricing | Unverified | See official pricing page |
| Performance benchmarks | Unavailable |